| VTRS |
Report |
Q2 2026 total revenue |
BEAT |
pred ~$3.71B vs. cons $3.66B |
MEDIUM |
| VTRS |
Report |
Q2 2026 adjusted EPS |
BEAT |
pred ~$0.63 vs. cons $0.61 |
MEDIUM |
| VTRS |
Report |
Q2 2026 adjusted EBITDA |
BEAT |
pred ~$1.06B vs. cons $1.03B |
LOW |
| VTRS |
Guide |
Total revenue guidance |
BETTER |
guide ~$14.80B midpoint vs. cons $14.78B (FY2026) |
MEDIUM |
| VTRS |
Guide |
Adjusted EBITDA guidance |
BETTER |
guide ~$4.42B midpoint vs. cons $4.39B (FY2026) |
MEDIUM |
| VTRS |
Guide |
Adjusted EPS guidance |
BETTER |
guide ~$2.49 vs. cons $2.47 (FY2026) |
MEDIUM |
| VTRS |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.3% |
— |
MEDIUM |
| VTRS |
Return |
5-day cumulative residual |
+0.9% (FADE) |
A modest Q2 beat and FY2026 guide slightly above consensus should drive an initially positive reaction, but the implied H2 adjusted EPS requirement of ~$1.27 versus consensus ~$1.27 leaves little room for upward revisions; higher launch and R&D spending should fade part of the day-1 gain. |
MEDIUM |